Skip to main content

Market Overview

Apellis Pharmaceuticals To Stop Testing APL-9 In Severe COVID-19 Patients

Share:
  • Following an interim review of mortality data by an independent data monitoring committee (DMC), Apellis Pharmaceuticals Inc (NASDAQ: APLSwill not pursue additional development of APL-9 for the treatment of severe COVID-19.
  • DMC reviewed data from the Phase 1/2 study of APL-9 found no meaningful reduction in the overall mortality rate in APL-9 combined with the standard of care arm, compared to standard of care alone.
  • No safety signals were observed. No additional endpoints were analyzed as part of the interim review by the DMC.
  • Apellis plans to provide full results in a scientific forum following the completion of the full data analysis.
  • APL-9 is designed to control the complement cascade centrally at C3 and may potentially treat a range of diseases caused by excessive or uncontrolled activation of complement.
  • Price Action: APLS shares closed 0.3% higher at $45.65 on Thursday.
 

Related Articles (APLS)

View Comments and Join the Discussion!

Posted-In: COVID-19 CoronavirusBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com